CTI BioPharma Corp. a biopharmaceutical company, develops, acquires, and commercializes oncology products for cancer treatment. Its development portfolio includes Pixantrone, a phase III trial product, for non-Hodgkin's lymphoma; Brostallicin, which is in a first-line Phase II study for the treatment of sarcoma; and OPAXIO, a chemotherapeutic agent for the potential treatment of non-small cell lung, ovarian, and other cancers. It has collaboration and licensing arrangements with Novartis International Pharmaceutical, Ltd.; and PG-TXL Company, L.P.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A
Frequently Asked Questions
What is Market Cap of CTI BioPharma Corp?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. CTI BioPharma Corp market cap is $1.2B.
What is the 52-week high for CTI BioPharma Corp?
52 week high is the highest price of a stock in the past 52 weeks, or one year. CTI BioPharma Corp 52 week high is $9.10 as of September 28, 2025.
What is the 52-week low for CTI BioPharma Corp?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. CTI BioPharma Corp 52 week low is $4.01 as of September 28, 2025.
What is CTI BioPharma Corp stock price today?
CTI BioPharma Corp stock price today is $9.09.
What was CTI BioPharma Corp stock price yesterday?
CTI BioPharma Corp stock price yesterday was $9.09.
What is the PE ratio of CTI BioPharma Corp?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. CTI BioPharma Corp’s P/E ratio is -15.78.
What is the Price-to-Book ratio of CTI BioPharma Corp?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. CTI BioPharma Corp P/B ratio is -47.2945.
What is the 50-day moving average of CTI BioPharma Corp?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. CTI BioPharma Corp 50-day moving average is $7.53.
